We failed to detect BRCA2 N372H polymorphism in drug‐sensitive recurrent ovarian cancer, but the BRCA2 polymorphism was present in 40% of drug‐resistant recurrent ovarian cancer patients. Here, BRCA2 is linked to ovarian cancer.